Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Research & Development (2019 - 2026)

Pliant Therapeutics has reported Research & Development over the past 8 years, most recently at $13.6 million for Q1 2026.

  • Quarterly Research & Development fell 68.73% to $13.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $79.3 million through Mar 2026, down 54.84% year-over-year, with the annual reading at $109.2 million for FY2025, 35.53% down from the prior year.
  • Research & Development was $13.6 million for Q1 2026 at Pliant Therapeutics, down from $15.6 million in the prior quarter.
  • Over five years, Research & Development peaked at $47.8 million in Q3 2024 and troughed at $13.6 million in Q1 2026.
  • The 5-year median for Research & Development is $32.2 million (2025), against an average of $30.4 million.
  • Year-over-year, Research & Development surged 47.67% in 2024 and then crashed 68.73% in 2026.
  • A 5-year view of Research & Development shows it stood at $25.1 million in 2022, then surged by 32.13% to $33.2 million in 2023, then grew by 16.91% to $38.8 million in 2024, then crashed by 59.83% to $15.6 million in 2025, then dropped by 12.84% to $13.6 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Research & Development are $13.6 million (Q1 2026), $15.6 million (Q4 2025), and $17.9 million (Q3 2025).